441 related articles for article (PubMed ID: 30239527)
1. Approval Process: An Overview of Biosimilars in the Oncology Setting.
Sowinski-Raff L
Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
[TBL] [Abstract][Full Text] [Related]
2. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
Sugay J
Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars: Exploring the History, Science, and Progress.
Tariman JD
Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
6. Nursing Roles: Clinical Implications Regarding Trends, Administration, and Education for Biosimilars in Oncology Practice.
Zack E
Clin J Oncol Nurs; 2018 Oct; 22(5):21-26. PubMed ID: 30239530
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.
Tomaszewski D
J Manag Care Spec Pharm; 2016 Aug; 22(8):919-26. PubMed ID: 27459654
[TBL] [Abstract][Full Text] [Related]
8. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
10. Similar names for similar biologics.
Casadevall N; Felix T; Strober BE; Warnock DG
BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
Hung A; Vu Q; Mostovoy L
J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
[TBL] [Abstract][Full Text] [Related]
14. [The story of biosimilars--chance or threat?].
Woroń J; Kocić I
Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
[TBL] [Abstract][Full Text] [Related]
15. The US approach to biosimilars: the long-awaited FDA approval pathway.
Calvo B; Zuñiga L
BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
[TBL] [Abstract][Full Text] [Related]
16. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
17. Assessment of pharmacists' views on biosimilar naming conventions.
Fernandez-Lopez S; Kazzaz D; Bashir M; McLaughlin T
J Manag Care Spec Pharm; 2015 Mar; 21(3):188-95. PubMed ID: 25726028
[TBL] [Abstract][Full Text] [Related]
18. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: The US Regulatory Framework.
Christl LA; Woodcock J; Kozlowski S
Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
[TBL] [Abstract][Full Text] [Related]
20. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
